Agilent BioHPLC columns Characterization of Antibody-Drug Conjugate Critical Quality Attributes

Characterization of Antibody‑Drug Conjugates and Related Conjugates — Agilent BioHPLC Workflows: Expert Summary

Importance of the topic
Antibody‑drug conjugates (ADCs) and emerging bioconjugates (antibody‑oligonucleotide conjugates, peptide/oligonucleotide drug conjugates) combine a biological targeting moiety with a potent payload. Their structural heterogeneity (variable drug‑to‑antibody ratio, DAR; multiple conjugation sites; glycoforms; aggregates/fragments) directly impacts potency, safety, pharmacokinetics and manufacturability. Robust, reproducible analytical workflows that resolve intact species, subunits, peptide maps, free payload and degradation products are therefore essential across discovery, formulation, stability testing, and QC release testing. The Agilent BioHPLC application compendium documents integrated solutions (sample prep, chromatography, mass spectrometry, and software) designed to address these ADC critical quality attributes (CQAs).
Objectives and overview of the compendium

• Present end‑to‑end workflows for ADC characterization at intact, subunit and peptide levels and for related conjugates (AOCs, ODCs, PDCs).
• Demonstrate analytical strategies for DAR determination, conjugation‑site mapping, free payload identification, aggregate/fragment profiling, payload stability and payload release assays.
• Compare chromatographic stationary phases and show how column chemistry and instrument design affect data quality under challenging mobile‑phase conditions (high salt, organic modifier, denaturing vs native).
• Provide practical method settings, automation procedures and software approaches that accelerate method development and generate reproducible, high‑confidence data.

Methodology and key analytical strategies

• Intact and subunit analysis: Reversed‑phase LC/MS with polymeric PLRP‑S columns (polystyrene/divinylbenzene, macroporous, silanol‑free) for denaturing intact mass and fragment work. Formic acid mobile phases yield narrow TIC peaks and good MS sensitivity compared to silica bonded phases when operated with PLRP‑S.
• Native mass analysis and DAR under native conditions: Hydrophobic interaction chromatography (HIC) for cysteine‑linked ADCs (AdvanceBio HIC columns) and native SEC for preserving noncovalent structure prior to extended mass‑range Q‑TOF detection. HIC uses high salt gradients (e.g., 1.5 M ammonium sulfate) and mild organic content to separate DAR species (D0‑D8).
• DAR determination workflows: Two complementary approaches — RP‑MS (intact/deglycosylated PLRP‑S LC/Q‑TOF with BioConfirm DAR calculator) and HIC‑UV (native separation by HIC with UV detection). Each has tradeoffs: RP‑MS provides mass confirmation and high sensitivity while HIC preserves native species and chromatographically resolves DAR isoforms.
• Peptide mapping and conjugation‑site identification: Automated digestion (reduction, alkylation, trypsin) and peptide mapping using AdvanceBio Peptide Mapping columns and LC/MS/MS data acquisition. Add MCC‑DM1 (or other linker/payload masses) as variable modifications in MassHunter BioConfirm to assign conjugated lysines or cysteines; example: 26 lysine conjugation sites confidently located in T‑DM1.
• Ligand‑binding LC/MS hybrid (LB‑LC/MS) workflows: Immunoaffinity capture on AssayMAP Bravo (streptavidin cartridges with immobilized antigen or biotinylated antibody; Protein A cartridges for payload release), on‑cartridge deglycosylation (PNGase F), and in‑solution digestion to clean complex matrices (plasma) prior to sensitive LC/Q‑TOF or triple‑quad quantification.
• Free drug and linker‑drug detection: Automated online 2D‑LC (SEC heart‑cut → RP) coupled to Q‑TOF provides online protein removal and separation of small, hydrophobic free drug (DM1) and linker‑drug species (SMCC‑DM1) without manual precipitation or SPE.
• Quantitative payload and surrogate peptide assays: AssayMAP‑enabled purification + tryptic surrogate peptides (conserved human IgG peptides) measured by triple quadrupole LC/MS (MRM) for protein quantitation; payload (e.g., MMAE) quantified by MRM with stable isotope internal standard after on‑cartridge enzymatic release (papain) or chemical cleavage.

Used instrumentation (summarized)

• Agilent sample automation: AssayMAP Bravo (streptavidin/Protein A cartridges), Protein Sample Prep Workbench.
• LC systems: Agilent 1290 Infinity II Bio LC (high‑salt and bioinert flow paths), 1290 Infinity II Bio 2D‑LC, Agilent 1260/1290 bio‑inert platforms.
• Columns: Agilent PLRP‑S polymeric RP (1,000 Å), AdvanceBio Peptide Mapping, AdvanceBio SEC (300 Å and 200 Å), AdvanceBio HIC, Poroshell EC‑C18 (small molecules), Bio SEC‑3 for native SEC.
• Mass spectrometers: Agilent 6530 / 6545XT AdvanceBio LC/Q‑TOF (extended dynamic and high‑mass modes), Agilent 6495 Triple Quadrupole for MRM quantification; Jet Stream/dual AJS ESI sources; extended mass range tuning and SWARM autotune for large complexes.
• Software: MassHunter Acquisition, MassHunter BioConfirm (integrated DAR calculator, peptide mapping), MassHunter Quantitative Analysis, MassHunter Qualitative, Agilent OpenLab CDS (blank subtraction for drifting HIC baselines).

Main results and discussion — highlights from the application notes

• PLRP‑S RP‑MS: PLRP‑S columns produced narrow TIC peaks for intact mAbs and lysine‑ADC species using FA/ACN mobile phases with excellent FWHM (≤0.1 min for mAbs) and improved MS signal compared to silica‑based RP under FA conditions.
• T‑DM1 in‑vitro transformation (LB‑LC/MS): Immunoaffinity capture + deglycosylation + LC/Q‑TOF resolved DAR0–DAR8; incubation at 37 °C in PBS or plasma for 4 days produced a clear shift toward lower DAR (avg DAR from ~3.5 to ~2.7) and revealed minor degradation products (e.g., hydrolyzed maytansinol species) by high‑resolution MS and peptide mapping.
• Brentuximab vedotin DAR and stability: Native SEC/HIC workflows with AssayMAP purification quantified DAR distribution in monkey plasma and showed rapid DAR decrease during incubation: average DAR dropped markedly in the first 1–3 days. Payload release assays (papain) and triple‑quad quantification tracked payload loss independently from protein concentration, revealing payload degradation while surrogate peptide levels remained stable.
• Conjugation‑site mapping: Automated peptide mapping and BioConfirm identified 26 MCC‑DM1 modified lysines in T‑DM1 with mass errors within ~3 ppm and high sequence coverage (~94%); stereoisomer peaks for DM1 conjugates were observed due to chiral centers in DM1 linker chemistry.
• SEC and HIC column evaluation: AdvanceBio SEC 300 Å with hydrophilic surface chemistry delivered superior monomer/dimer resolution and lower nonspecific interaction versus competing SEC stationary phases for both lysine‑ and cysteine‑linked ADCs. HIC columns (AdvanceBio HIC) combined with bio‑inert LC hardware and blank‑subtraction processing provided reproducible DAR quantitation (e.g., DAR ≈ 3.7 for brentuximab vedotin, RT RSD <0.081%).
• 2D‑LC for free drug: Heart‑cut SEC → RP 2D‑LC enabled automated online protein removal and unambiguous identification of free DM1 and SMCC‑DM1 (accurate masses, low ppm) avoiding offline precipitation workflows.
• Native MS for labile conjugates (mAb‑siRNA): Under native SEC and extended mass range Q‑TOF settings, intact mAb‑siRNA conjugates (DAR1) were detected and deconvoluted; denaturing RP‑MS broke labile conjugates and produced many degraded fragments, demonstrating the value of native LC/MS for labile payload chemistries.

Benefits and practical applications of the described methods

• Comprehensive CQA coverage: integrated intact, subunit, peptide mapping, charge variant and glycan analyses tailored for ADCs and next‑generation conjugates.
• Matrix robustness: immunoaffinity capture (AssayMAP) enables sensitive analysis from plasma with reduced background and reliable quantitation in complex matrices.
• High confidence DAR and structural assignments: combination of chromatographic separation and high‑resolution MS plus dedicated software (BioConfirm) automates DAR calculation and improves traceability for regulatory submissions.
• Time and resource efficiency: automated sample prep, standardized column chemistries, and 2D‑LC online cleanup reduce manual steps and method development times compared with classical SPE or precipitation workflows.
• Versatility: methods can be adapted for ADCs, AOCs, ODCs and PDCs by selecting appropriate stationary phases (SEC/HIC/RP), digestion enzymes (IdeS, papain, trypsin) and MS acquisition modes (native vs denaturing).

Future trends and applications

• Broader adoption of native LC/MS and extended mass‑range MS for labile conjugates (AOCs/AOCs) and intact oligonucleotide payloads.
• Increased use of 2D‑LC-MS (heart‑cut and comprehensive modes) for automated online cleanup and orthogonal separation of small payloads vs protein matrix.
• Tighter integration of automated sample‑prep platforms with LC/MS and data pipelines to support high‑throughput stability, PK/PD and biotransformation studies.
• Software advances (automated peak‑annotation, deconvolution, machine learning‑assisted spectral interpretation) to accelerate conjugation‑site assignment, degradation product identification and comparability assessments.
• Method standardization efforts for regulatory acceptance of LC/MS‑based DAR and payload assays as orthogonal or replacement methods to ligand binding assays in bioanalysis programs.

Conclusions
Integrated Agilent BioHPLC workflows combine polymeric RP, peptide mapping columns, SEC, HIC, 2D‑LC and robust sample automation with high‑resolution and triple‑quad MS to comprehensively characterize ADC CQAs. Key advantages shown across the compendium include reliable DAR determination (native HIC or intact RP‑MS), high‑resolution conjugation‑site mapping, sensitive free payload detection via 2D‑LC, and the preservation of labile conjugates using native SEC‑MS. Careful selection of stationary phase, mobile‑phase composition, sample prep and bioinert LC hardware are critical to minimize secondary interactions and obtain reproducible, high‑confidence data for discovery, development and QC.
Reference

• Beck A., Reichert J.M. Antibody‑drug conjugates. mAbs 2014, 6(1):15–17.
• McCalley D.V. Effect of buffer on peak shape of peptides in reversed‑phase HPLC. J Chrom A 2004, 1038:77–84.
• Lambert J.M., Chari R.V. Ado‑Trastuzumab Emtansine (T‑DM1): an ADC for HER2‑positive breast cancer. J Med Chem 2014, 57:6949–6964.
• Kim M.T., Chen Y., Marhoul J., Jacobson F. Statistical modeling of drug load distribution on trastuzumab emtansine. Bioconjugate Chem 2014, 25:1223–1232.
• Marcoux J. Native MS and ion mobility characterization of trastuzumab emtansine. Protein Sci 2015, 24:1210–1223.
• He J.T., Yu S.F., Yee S., et al. Characterization of in vivo biotransformations for trastuzumab emtansine by high‑resolution accurate‑mass MS. mAbs 2018, 10(7):960–967.
• Jenkins R., Duggan J.X., Aubry A.F., et al. Recommendations for validation of LC–MS/MS bioanalytical methods for protein biotherapeutics. AAPS J 2015, 17(1):1–16.
• Agilent application notes cited in the compendium (selected): PLRP‑S and AdvanceBio workflows for intact and peptide‑level ADC analysis; 2D‑LC/Q‑TOF free drug identification; HIC DAR analysis on bio‑inert 1290 Infinity II platforms; AssayMAP Bravo immunoaffinity sample prep workflows.